WFDC2 and ovarian carcinoma: The utility of SPON1 alone or together with CA-125 [20–27] and/or Human epididymis protein 4 (HE4) [22, 28] should be determined in future experiments using serum samples from patients with ovarian cancer, other benign and malignant tumors, as well as samples from healthy individuals.